Samumed CMO Hopes To Reach Drug Approvals Via The Wnt Pathway
The clinical-stage biotech has diverse pipeline generated by its Wnt signalling pathway technology platform, and aims to get its first drug to market in 2020.
You may also be interested in...
Highlights from the past year's financings include BeiGene's $800m follow-on offering in the US and $903m Hong Kong IPO, Moderna's $560m Series G round and $604m IPO, and Allogene's $300m Series A and $373m IPO.
Global financings for cell and gene therapy and tissue engineering companies more than doubled in the second quarter; financings for the sector rose 79% in the first half of 2018. Also, Samumed leads recent venture funding deals with a $438m round.
An expanded $120m series C financing will help Freeline advance its lead program in hemophilia B into a pivotal trial next year, CEO Theresa Heggie tells Scrip.